XORTX Therapeutics Inc (V:XRTX) — Market Cap & Net Worth
Market Cap & Net Worth: XORTX Therapeutics Inc (XRTX)
XORTX Therapeutics Inc (V:XRTX) has a market capitalization of $3.55 Million (CA$4.91 Million) as of June 16, 2026. Listed on the V stock exchange, this Canada-based company holds position #29205 globally and #1379 in its home market, demonstrating a -5.06% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying XORTX Therapeutics Inc's stock price CA$3.00 by its total outstanding shares 6962218 (6.96 Million). Review XORTX Therapeutics Inc debt and liabilities to assess the company's total debt and financial obligations.
XORTX Therapeutics Inc Market Cap History: 2015 to 2026
XORTX Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows growth from $6.04K to $15.11 Million (105.30% CAGR).
XORTX Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how XORTX Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of XRTX by Market Capitalization
Companies near XORTX Therapeutics Inc in the global market cap rankings as of June 16, 2026.
Key companies related to XORTX Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #443 globally with a market cap of $63.36 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $450.46 |
| #443 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.36 Billion | $614.98 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €259.20 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €761.20 |
XORTX Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, XORTX Therapeutics Inc's market cap moved from $6.04K to $ 15.11 Million, with a yearly change of 105.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$15.11 Million | +289.61% |
| 2025 | CA$3.88 Million | -54.44% |
| 2024 | CA$8.51 Million | -41.72% |
| 2023 | CA$14.61 Million | -96.80% |
| 2022 | CA$456.90 Million | -55.20% |
| 2021 | CA$1.02 Billion | +139555.17% |
| 2020 | CA$730.27K | -9.38% |
| 2019 | CA$805.82K | +9900.00% |
| 2018 | CA$8.06K | +128.57% |
| 2017 | CA$3.53K | -99.12% |
| 2016 | CA$402.91K | +6566.67% |
| 2015 | CA$6.04K | -- |
End of Day Market Cap According to Different Sources
On Jun 16th, 2026 the market cap of XORTX Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.55 Million USD |
| MoneyControl | $3.55 Million USD |
| MarketWatch | $3.55 Million USD |
| marketcap.company | $3.55 Million USD |
| Reuters | $3.55 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About XORTX Therapeutics Inc
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the … Read more